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The Pulmonary Microbiome in 
Cystic Fibrosis
Freddy J. Frost, Dilip Nazareth and Dennis Wat
Abstract
The chronic colonisation of the lower airways by bacterial pathogens is the 
leading cause of morbidity and mortality in patients with cystic fibrosis (CF). The 
use of novel culture-independent techniques such as next-generation sequencing 
(NGS) to analyse the lungs has allowed us to further understand the diversity, the 
complexity, the effects of acute exacerbations and the use of antibiotics on the 
bacterial communities. The understanding of the CF microbiome to airway disease 
remains a fascinating area of research; it presents new opportunities for disease 
management in CF and has the potential to explore the effects of cystic fibrosis 
transmembrane conductance regulator (CFTR) modulators. It also allows further 
appreciation regarding the roles played by anaerobic organisms within the CF 
airways. It is also of interest that a number of studies have demonstrated that the 
fluctuations of microbiome are not necessarily associated with the patient’s clinical 
status. Despite the available evidence, there remain many challenges that must be 
overcome if microbiome profiling is going to influence future clinical practice. The 
effects of fungus and the emergence of nontuberculous mycobacteria in CF are also 
briefly discussed in this chapter.
Keywords: cystic fibrosis, microbiome, CFTR modulators, nontuberculous 
mycobacteria, Aspergillus
1. Introduction
Traditional culture techniques rely on growing bacteria on media in laboratory 
conditions often optimised for growth of specific organisms so that they can then 
subsequently be identified. In the last 20 years, novel techniques utilising next-
generation sequencing (NGS) to identify bacteria have become available, enabling 
detection and description of bacterial communities without the need for conven-
tional culture. These technologies have allowed a greater understanding of bacterial 
communities throughout the human body and have revealed functional roles in 
both health and disease.
A healthy human gut, for example, is home to a highly diverse community of 
bacteria, termed as microbiome, which has symbiotic functions including metab-
olism of otherwise indigestible compounds and defence against opportunistic 
pathogens [1, 2]. Furthermore, bacteria in the gut influence the stimulation and 
development of the innate mucosal immune system [3]. In addition to the roles 
in health, there has been significant interest in the relationship between micro-
biomes and diseases such as obesity, inflammatory bowel disease and diabetes 
mellitus [4–6].
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Studies utilising culture-independent techniques to analyse the lungs have iden-
tified the presence of bacterial communities that are much more complex than the 
previously appreciated. The lungs were long considered to be an inherently sterile 
environment, in part due to the fact that conventional culture techniques often 
yielded negative results during health and it was only during disease that pathogens 
were detected. However, the advent of culture-independent techniques has demon-
strated that multiple organisms comprise a community, termed the ‘microbiome’, 
in the lungs of patients, both healthy and diseased [7–9]. In this chapter, we discuss 
the techniques employed in 16S rRNA sequencing and the evidence these tech-
niques have generated so far in relation to cystic fibrosis.
2. 16S rRNA gene sequencing
The 16S rRNA gene codes for a ribosomal subunit present in nearly all bacteria. 
The gene itself is approximately 1.5 kb long and consists of conserved regions, 
similar in nearly all microorganisms, and nine variable regions labelled, V1–V9, 
which are practically specific to each microorganism [10]. The identification of a 
specific DNA sequence that corresponds to the known variable region of 16S rRNA 
gene can allow discrimination of the presence and relative abundance of different 
microorganisms (Figure 1).
Once the samples have been processed, DNA is extracted, and the 16S rRNA 
gene is amplified using polymerase chain reaction (PCR). Next-generation 
sequencing allows elucidation of the precise gene sequences, and online reference 
databases can then be used to match each sequence to an organism and quantify its 
relative proportion within a multispecies population. However, it is important to 
note that sequencing of the 16S rRNA gene has limited resolution and often cannot 
distinguish species with similar gene sequences apart. Therefore, instead of distinct 
species, sequences are referenced against and assigned into operational taxonomic 
units (OTU) (see Table 1).
Given the large number of species identified even in healthy lungs, ecological 
theory and analyses are often employed to understand community dynamics [9]. 
According to ecological principles, the composition of the lung microbiome is 
determined by three factors:
1. Immigration of organisms into the lung
2. Elimination of microbes from the airways
3. Regional growth factors [11]
Figure 1. 
Schematic illustration of structure of the 16S rRNA gene. Orange regions—variable regions; blue region—
conserved region.
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The lung microbiome in healthy individuals is dictated largely by immigration 
and elimination and hence generally consists predominantly of those Gram-
negative anaerobes also resident in the oral flora such as Prevotella and Veillonella 
spp. [11]. However, in disease the regional growth conditions are altered, and 
niches for other species to thrive are created. In CF, for example, viscous secre-
tions, altered pH, nutrient availability and architectural disturbance may all help 
select for a community of altered composition to that of healthy individuals. How 
this community changes over time, in response to the intensive antibiotic treat-
ment that people with CF are exposed to, has been the subject of much interest in 
the last decade.
3. CF respiratory microbiota in early life
Understanding the development of the CF respiratory microbiota in early life 
has attracted interest in order to appreciate the driving factors behind the distinct 
microbiota seen later in life and also to identify potential opportunities for inter-
vention. Neonates and infants cannot expectorate sputum independently, and 
bronchoalveolar lavage (BAL) is only used sparingly; hence, upper respiratory 
tract samples are often used as surrogates. The imperfection of this approach was 
recently highlighted where large differences in concordance between BAL samples 
and upper respiratory tract (URT) samples were observed in some taxa [12]. 
Nevertheless, concordance was high for some important taxa such as Moraxella and 
Staphylococcus, and in the absence of less invasive techniques, URT sampling enables 
early estimation of the neonatal lower respiratory tract.
The composition of CF nasopharyngeal microbiota diverges from that of 
non-CF infants as early as the first few months of life [13, 14]. Newborn healthy 
infants appear to have nasopharyngeal microbiota dominated by Moraxella spp., 
Corynebacterium spp. and Haemophilus spp., a community structure that persists for at 
least the first 6 months of life. Conversely the CF nasopharynx microbiome is initially 
dominated by Staphylococcus aureus before a gradual increase in Streptococcus spp. and 
Moraxellaceae at 3 months of age [13]. Despite the increased S. aureus seen in CF, there 
were no decreases in measures of richness or diversity indicating that changes are due 
to differing microenvironment rather than interspecies competition [15].
Term Definition
Microbiome The microorganisms in a particular environment
16S rRNA gene A gene which codes for a ribosomal subunit. Present in all prokaryotes and has 
variable regions, which differ slightly between bacterial species
Richness A measure of the number of species in a community
Evenness A measure of similarity of the relative abundance for each species in a 
community That is, does one species dominate, or do all species have similar 
relative abundance?
Diversity A measure of variety in a community. Combination of richness and evenness
Alpha diversity Within-sample diversity
Beta diversity Between-sample diversity
Operational 
taxonomic unit (OTU)
Group of strains/species with similar 16S rRNA gene sequences
Table 1. 
Glossary of terms and definitions.
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The divergence observed in the first few months of life usually precedes antibi-
otic administration and demonstrates that CF itself is associated with compositional 
changes in the microbiota, but as CF infants grow older, exposure to antibiotics, 
either via acute treatment for respiratory illnesses or prophylaxis against classic CF 
pathogens, becomes inevitable. Mika et al. investigated the relationship between 
antibiotics and the nasal microbiota by prospectively following 30 newborn infants 
with CF with fortnightly sampling for the first 12 months of life [14]. Antibiotic 
administration was associated with an increase in the Shannon diversity measure  
(a measure of the richness and evenness of a community), but this was judged to be 
most likely secondary to an increase in transient colonisers. Interestingly, antibiotic 
therapy was staphylococcal directed, but decreases in Staphylococcus OTUs were 
not seen. Instead significant reductions in Moraxellaceae were observed, and when 
oligotyping was used to observe changes in Staphylococcus at the species level, mild 
reductions in S. aureus were offset by increases in S. epidermidis, leading the authors 
to suggest that S. epidermidis may act as a reservoir of resistance. These findings 
were supported by Prevaes et al. who conducted a similar study in a slightly older 
population (mean age 2 years old) [13]. Antibiotic treatment was observed to be 
associated with reductions in Moraxellaceae and S. aureus OTUs, with increases in 
other staphylococcal OTUs, although more specific oligotyping was not performed.
As babies grow older, sampling from the lower airways becomes more common, 
and comparisons between the lower and upper airways become feasible. Given the 
close proximity and interrelated spaces of the nose, throat and lungs, it could be 
expected that they all may share similar community structures; however, the reality 
is that the nasal community appears different from that of the throat and lung, 
which are much more closely aligned. Boutin et al. found differences in the commu-
nity structure of the nasal cavity compared to throat and sputum samples; in that 
diversity, richness and evenness were significantly higher in nasal samples, and up 
to 21 of the 76 most abundant nasal OTUs were not present in the throat or sputum 
samples [16]. Interestingly, the authors also found that subjects could be broadly 
defined into one of two ecotypes based on the presence or absence of Pseudomonas, 
and the similarities between throat and sputum samples began to diminish once 
Pseudomonas was present. Muhlebach et al. supported these findings in a recently 
published study, which for the first time included routine sequential BAL sam-
pling in young children as part of the large AREST-CF cohort in Australia and the 
USA. They showed that lower airway cultures mirrored that of the oral cavity until 
approximately age 2, when increasing predominance of known CF pathogens was 
observed and communities diverged [17]. This has a number of clinical implica-
tions in that, firstly, throat swabs can provide adequate representation of the lower 
airways in very young children and, secondly, prevention or delay of this transition 
point by manipulation of the microbiota could theoretically be a strategy to improve 
outcomes later in life.
4. Progressive loss of diversity
Once the lungs are colonised with CF pathogens, a pattern of progressively 
uneven community structures ensues. Cox et al. examined biobanked sputum 
samples from a cohort of 63 clinically stable people with CF of ages ranging from 
9 months to 72 years [7]. This cross-sectional approach identified the loss of 
community richness, evenness and diversity as age increased. Pseudomonas and 
Burkholderia OTUs began to progressively dominate in older subjects, and the 
changes in community structure were inversely associated with pulmonary func-
tion. In a similar study design with 269 patients, Coburn et al. also found sample 
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diversity inversely correlated with age and disease stage. Progressive loss of diver-
sity was particularly correlated with Pseudomonas and Burkholderia abundance, 
which notably increased after the age of 25 [18].
Zhao et al. were the first to confirm these findings longitudinally when they 
followed up six patients over a 9-year period with serial sputum collections. It 
was observed that the three patients with what they termed as more ‘progressive’ 
disease had significant decreases in community diversity over the course of several 
years. Decreasing lung function and increasing age were also associated with 
decreasing community diversity [19]. This study was soon followed by Fodor et al. 
who focussed more on changes in the microbiota associated with acute changes in 
clinical status but did observe a strong correlation between low species richness and 
poor lung function [20]. Stokell et al. followed up a single patient up to over 3 years 
and observed increasing total bacterial load as well as diminishing community 
richness and diversity [21].
Contrastingly, Whelan et al. recently published a study of six patients who 
submitted thrice-weekly sputum samples for a year [22]. No overall changes in 
community structure were observed over the course of the year, and the authors 
concluded that the respiratory microbiome is unique to each patient and the previ-
ously reported associations between community structure and clinical parameters 
may be true on a cohort/population level but not at an individual level. There is 
some merit in this argument, but it is also worth noting that the six patients in 
the study appeared relatively stable with a median of only one exacerbation in the 
12-month study period. It is also therefore a possibility that the follow-up period 
was not long enough to capture the more indolent changes likely to be present in 
those patients [23]. A much longer study period was adopted by Acosta et al. [24] 
who analysed samples from matched patients with biobanked sputum samples 
in three historic cohorts spanning nearly 20 years at a single centre. Across all the 
three cohorts, the core microbiome constituents were preserved, but the propor-
tion of Pseudomonas-dominated communities was reduced, and overall diversity 
increased in the more recent cohorts. Community structure improved gradually 
from the most historic cohort to the most recent, and these changes appeared to 
correlate with the generally improving clinical status of people with CF, confirming 
the previously described observed association between community structure and 
clinical outcomes [24].
The association reported in most studies between community structure and 
clinical outcomes has inevitably led to the question of whether a less diverse or even 
rich microbiome is simply a marker of increased pulmonary disease or is itself a 
driver in disease pathogenesis [25]. If the latter were true, efforts to promote a more 
diverse community could have the potential to slow pulmonary disease progression. 
An Italian group has led efforts to find patterns or signatures in the microbiome 
that may predispose patients to accelerated lung function decline; however, no 
causal association has been elucidated [26–28]. Instead, Zhao et al. found that the 
relationship between age, lung function and community diversity disappeared once 
controlled for antibiotic use, thus suggesting antibiotic therapy is the predominant 
driver of reducing community diversity [19]. The same group later developed a sta-
tistical approach to more precisely correct the antibiotic exposure when examining 
relationships between microbiota and clinical outcomes. The approach was applied 
to 478 sputum samples and confirmed that antibiotic use was an independent 
predictor for decreased diversity [29].
Accurately recording antibiotic use is troublesome in longitudinal studies due to 
the frequent episodic use of antibiotics in CF which is often self-directed by patients 
themselves, due to the widespread use of long-term antibiotics for which compli-
ance may be heterogeneous and also due to the retrospective nature of a number 
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of CF microbiome studies [30]. However, Pittman et al. were able to prospectively 
perform bronchoscopy and record antibiotic exposure of 32 subjects as part of the 
AREST-CF study. In that study, community diversity was much lower in the BAL of 
those patients receiving antibiotics [31].
Thus it appears likely that the strong association between community structure 
and degree of lung disease is related to the inevitable prolonged and aggressive use 
of antibiotics in CF rather than direct pathogenesis from a less diverse microbiome.
5. Community changes with acute pulmonary exacerbations
Despite the importance of exacerbations on long-term outcomes of people with 
CF, the pathophysiology of these events remains undefined [32, 33]. Clinically, 
exacerbations are frequent and are characterised by rapid changes in symptoms 
such as an increase in sputum volume or purulence, shortness of breath and fatigue. 
The precise mechanisms underlying these important events remain elusive, and 
studies looking for answers using culture-independent techniques have not found 
consistent answers. For example, one may expect to find evidence of increases in 
known pathogens at the time of exacerbations, yet there is no consistent evidence of 
this [23]. In fact, a number of studies have found the CF microbiota to be extremely 
stable over time and resilient to change at exacerbation and following subsequent 
treatment [19, 20, 34, 35].
However, when the community structure as a whole is considered, a number 
of larger studies have found reduced diversity or richness at the times of exacerba-
tion compared to clinical stability. Coburn et al. found small decreases in Shannon 
diversity in exacerbation samples compared to their baseline study of 269 people 
with CF [18]. Similarly, Filkins et al. found that samples taken during exacerbations 
had significantly lower diversity than samples taken when patients were stable 
[36]. Perhaps most convincingly, Li et al. collated data from 18 previous studies to 
analyse over 700 sputum samples and found that there were significant reductions 
in community richness at exacerbation [37].
Whilst increases in P. aeruginosa at the time of exacerbation have not been seen 
consistently, they have been observed in some cases. Carmody et al. followed up 
four patients for 3 months with daily sputum sampling and observed daily stability 
between exacerbations but increased P. aeruginosa abundance at the time of exac-
erbation in some patients and increases in Prevotella in others [38]. These findings 
help introduce two new concepts: firstly, the potential for exacerbations to appear 
similar phenotypically but have different underlying aetiology with only some 
being due to changes that can be observed in the microbiota and, secondly, that 
previously overlooked anaerobes may play a pathogenic role.
The first concept is supported by Whelan et al. who found in longitudinal 
sampling of six patients that some but not all exacerbations were associated with 
changes in the microbiota [22]. Attempts to identify different types of exacerba-
tions in COPD have identified four distinct aetiological clusters, bacterial, viral, 
eosinophilic predominant and ‘paucinflammatory’, and even though these clusters 
may not be mirrored in CF, it is plausible that not all exacerbation clusters would 
be associated with changes apparent in either individual taxa or overall bacterial 
community structure [39].
Changes in the metabolic activity of specific taxa or the community as a whole 
triggering an exacerbation could be another explanation for an apparent lack of 
change in the community structure seen in some studies. The metabolites lactate 
and putrescine were found by Twomey et al. to increase during exacerbation in 
the absence of clear changes in the community structure [40]. Quinn et al. used 
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the ecological functional networking to identify the non-mevalonate pathway of 
isoprenoid synthesis as a ‘keystone’ pathway in CF infections. Intriguingly fosmido-
mycin, an antimalarial agent, is known to be effective at targeting this pathway [41].
The second concept to emerge from the study of Carmody et al. relates to the 
changes in Prevotella abundance at the time of exacerbation and raises the prospect 
that species not considered conventional CF pathogens may play a role in exac-
erbations [42]. Anaerobic species are easily overlooked in conventional selective 
culturing due to the requirement for anoxic culture yet are identified frequently in 
culture-independent analyses of the CF lower airways. In addition to Gemella, both 
Prevotella and Streptococcus anginosus (milleri) have been found to have associations 
with clinical stability [36, 38, 42]. Anaerobes have been shown to have the potential 
to modulate P. aeruginosa gene expression in the polymicrobial setting; hence, even 
if they are not directly pathogenic, they may still play a contributory role to the 
pathogenesis of some exacerbations [43, 44].
To summarise, the aetiologies underpinning the transition from a stable state 
to an acute exacerbation are not well understood. It is likely that there multiple 
aetiological clusters but only some of which may be associated with changes in 
community structure.
6.  Community changes associated with treatment for acute pulmonary 
exacerbations
Traditional dogma would dictate that intensive, targeted antimicrobial therapy 
with dual anti-pseudomonal agents will result in significant reductions in abun-
dance of P. aeruginosa; however, in a similar vein to the findings from studies of 
the onset of exacerbations, microbiota responses to treatment for acute pulmonary 
exacerbations in CF have not aligned with this conventional understanding of 
infections.
One of the predominant themes that has emerged from studies of the respira-
tory microbiota response to acute antibiotics is that P. aeruginosa is not impacted to 
the same degree as other members of the community. For example, Daniels et al. 
studied 12 adult CF subjects across the cycle of an exacerbation and treatment and 
found that following initiation of anti-pseudomonal antimicrobials, the relative 
abundance of P. aeruginosa actually increased, alongside a reduction in the total 
number of species detected [45]. Cuthbertson et al. also found no evidence of 
reduced P. aeruginosa abundance in a study of 12 CF patients receiving treatment 
for pulmonary exacerbations [45]. Instead, reductions in Streptococcus sanguinis, 
Prevotella and Porphyromonas OTUs were observed [35]. Similarly, Li et al., in 
their analysis of over 700 sputum samples, found that antibiotic treatment had 
no effect on Pseudomonas abundance but did have significant effects on Gemella, 
Staphylococcus, Actinomyces, Moraxellaceae and Fusobacterium [37]. Further, Fodor 
et al. again found that dominant taxa such as Pseudomonas and Burkholderia were 
unchanged when compared at the beginning and end of an exacerbation but the 
relative abundances of Gemella, Streptococcus and a small number of other less 
abundant OTUs were all reduced [20].
In contrast, two studies have found reductions in P. aeruginosa following treat-
ment. Firstly, Zemanick et al. investigated the association between inflammation 
and changes to the airway microbiota during treatment for exacerbations and found 
that although bacterial load did not change, the relative abundance of P. aeruginosa 
was observed to decrease and that these changes correlated with improved lung 
function [46]. A reduction in P. aeruginosa abundance following treatment was also 
reported by Smith et al., who noted rapid decreases in P. aeruginosa abundance and 
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an associated increase in diversity following the initiation of intravenous antibiotic 
treatment for pulmonary exacerbations in CF, although these changes were tran-
sient and returned to baseline following the completion of treatment [47].
There are a number of factors that may explain the differences between the 
studies mentioned in this section, and many of them apply to studies of the CF 
microbiome in general. The most obvious is the heterogeneous study designs, 
which are mostly retrospective and observational in nature and include a wide 
range of antibiotic regimens. For example, some authors such as Cuthbertson and 
Daniels included exacerbations treated with oral antibiotics as well as those requir-
ing intravenous therapy [35, 45]. Milder exacerbations are often treated with oral 
antibiotics, and hence associated changes in the microbiota may also be expected to 
be more subtle. Even in those studies where only intravenous regimens were used, 
the antibiotic regimens or doses given are often not listed. The lack of a control or 
comparator group further makes interpreting results difficult [35, 45].
A further consideration is the sampling timeframes in each study, where again 
there exists a considerable variation that may have implications for interpreting 
results, particularly given that Smith et al. reported significant but transient reduc-
tions in P. aeruginosa abundance in the first few days of treatment [48].
Sample collection, storage, handling and DNA extraction techniques all also 
have the potential to impact on subsequent sequencing results. For example, mul-
tiple freeze–thaw cycles have been demonstrated to affect the results of microbiota 
analysis in respiratory samples [49]. Furthermore, different sequencing platforms 
can also produce different profiles [50].
There is no universally standardised protocol for the extraction of DNA from 
respiratory samples, and hence methods are often inconsistent between study 
groups. One obvious inconsistency is the use of propidium monoazide (PMA), a 
chemical compound that binds DNA in cells with damaged membranes and hence 
allows exclusion of non-viable DNA from sequencing. Excluding non-viable DNA 
has been suggested to be important for accurately identifying which members of 
the community are active at times of exacerbation and helps to avoid overestimation 
of viable microorganisms following treatment with antibiotics, but it is not utilised 
by all groups [51, 52]. There are concerns that PMA may incompletely penetrate 
sputum, hence only identifying a portion of non-viable cells. PMA is also known 
to stain viable cells of some species and stain dead cells in others [53]. In CF exac-
erbations, PMA treatment was not found to significantly alter the community as a 
whole, and only changes in low abundance ‘satellite’ taxa were apparent [51].
Overall, there is certainly evidence that acute antibiotic administration alters 
the respiratory microbiota; however, in the absence of prospective controlled trials, 
it is difficult to interpret these results given the confounders mentioned above. 
Indeed there have been calls for future clinical trials in CF to include biobanking of 
samples to allow a more rigorous scrutiny of the effect of antibiotic agents on the 
 microbiome [54].
7. Community changes associated with chronic suppressive antibiotics
Inhaled antibiotics such as colistimethate (COL), tobramycin (TOB), aztreo-
nam (AZLI) and levofloxacin (LIS) preparations are all licenced in the UK for the 
treatment of chronic P. aeruginosa infections and have, to varying degrees, dem-
onstrated improvements in lung function and exacerbation rates as well as sputum 
density of P. aeruginosa [55–58]. However, despite the near ubiquitous use of these 
inhaled anti-pseudomonals in the chronic P. aeruginosa treatment in CF, the effect 
of these treatments on the microbiome remains poorly defined. Furthermore, 
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many patients receive chronic macrolide therapy over many years, at least in 
part for its immunomodulatory effects, yet similarly little is known about the 
effects of this persistent selective pressure on the microbiota. When considering 
inhaled antibiotics, there is contrasting evidence as to their influence on the CF 
microbiome. For example, Kramer et al. [59] did not find any correlation between 
bacterial community structure and inhaled antibiotic treatments, although it is 
unclear which agents patients were using in that study. More recently Acosta et al. 
[24] utilised a prospectively collected Canadian sputum biobank primarily to 
investigate changes in CF cohort microbiota over time but also assessed whether 
different long-term antibiotics were associated with distinct microbiota. Eighty-
two samples from 42 patients were sequenced, and those receiving long-term 
tobramycin and colistimethate harboured significantly different respiratory com-
munities compared to those who were not, but interestingly no differences were 
seen in people receiving AZLI. The authors also assessed the impact of long-term 
oral azithromycin and nebulised dornase, but these agents were not associated 
with any differences. Perhaps intrigued by the failure of AZLI to be associated 
with microbiomic differences given its proven clinical benefits, the same group 
investigated its effects in more detail. In the only published study focussing on the 
microbiomic outcomes of a specific inhaled antibiotic, Heirali et al. [54] utilised 
the same Canadian biobank and sequenced 80 samples from 24 patients naive to 
AZLI and 82 samples from the same patients following initiation of AZLI. Overall 
no differences were observed in alpha or beta diversity measures, but at the OTU 
level, significantly lower relative abundances of Prevotella were seen following 
AZLI initiation. The authors then subclassified patients into AZLI ‘responders’ 
and ‘non-responders’ based on clinical outcomes and found ‘non-responders’ to 
have lower abundance of Pseudomonas and higher abundance of Staphylococcus. 
This novel approach raises the prospect of signatures in an individual’s microbiota 
acting as a biomarker for response to antibiotics and may represent an important 
step in the march towards personalised precision medicine in CF. Further stud-
ies are required to explore the potential for an individual’s microbiota to guide 
treatment.
8. Community changes associated with CFTR modulators
In the last 5 years, treatments targeted towards correcting the underlying 
defect in CF have become available. Ivacaftor, a cystic fibrosis transmembrane 
conductance regulator (CFTR) potentiator, is licenced specifically for the treatment 
of people with a G551D mutation and a number of other rare gating mutations, 
which together account for approximately 5–10% of the CF population in the UK 
[60]. In this subset of the CF population, ivacaftor use has been associated with 
improvements in lung function, reductions in exacerbations, reductions in sweat 
chloride, improved weight gain and improved quality of life [61, 62]. The restora-
tion of CFTR activity by ivacaftor and the associated clinical benefits, in particular 
improved lung function and reductions in exacerbation, has inevitably raised 
questions as to whether ivacaftor has an antimicrobial effect.
Theoretically, ivacaftor could have an antimicrobial effect in a number of 
ways. Firstly, the restoration of CFTR activity should result in a rehydrated airway 
surface layer, and this in turn will allow the mucociliary escalator to function 
physiologically. The improved clearance of airway secretions would then result 
in the elimination of bacteria. Secondly, the restoration of CFTR activity could 
result in a dramatic change in the local pulmonary microenvironment, turning a 
previously favourable environmental niche into an inhospitable one for resident 
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microbiota. There is evidence to support a similar effect in the GI tract, where 
CFTR modulation with ivacaftor was associated with improved proximal small 
intestinal pH, likely secondary to improved bicarbonate secretion [63]. Thirdly, 
a direct bactericidal effect of ivacaftor itself has been postulated given that its 
chemical structure contains a quinolone ring and many quinolone derivatives have 
antimicrobial properties [64]. This theory is supported by evidence that ivacaftor 
exerted in vitro antibacterial effects on clinical respiratory isolates of S. aureus 
(MSSA and MRSA) and Streptococcus pneumoniae [65, 66]. However, these studies 
found very little activity against Gram-negative organisms, which is uncharacter-
istic of a quinolone-based antibiotic [65]. Interestingly, the authors of the same 
study noted synergism of ivacaftor with antibiotics commonly used in CF, and 
this was recently supported by Payne et al., who again found that ivacaftor had 
activity against Streptococcus spp. and S. aureus and that the effect was potentiated 
in the presence of tobramycin. Again there was no evidence of direct antibacterial 
 activity against P. aeruginosa [67].
Interest has since focussed on clinical microbiological outcomes of patients com-
menced on ivacaftor therapy in an effort to investigate differences post-treatment 
initiation. Interestingly, despite ivacaftor appearing to have no innate activity 
against P. aeruginosa, a number of studies have reported reductions in counts and 
density post initiation, perhaps suggesting that quinolone activity is not the only 
mechanism at play [68, 69].
In contrast to the relative lack of focus on inhaled antibiotics, a number of 
studies have investigated the effects of ivacaftor on the respiratory microbiome. 
Peleg et al. [70] conducted the only placebo-controlled trial in this field when they 
performed a double-blind, placebo-controlled, cross-over study of 28-day ivacaftor 
treatment. Sputum was collected at the start and end of each 28-day treatment 
period, and 16S rRNA sequencing with qPCR correlation was subsequently per-
formed. No significant differences were observed for either total bacterial load or 
P. aeruginosa load following ivacaftor therapy, and no significant difference in the 
microbiota composition (based on 16S rRNA microbiome analysis) was observed 
between the placebo and treatment samples. However, the authors noted that when 
they adjusted for consistent or changing antibiotic exposure in the 28-day study 
period, ivacaftor was associated with a significant reduction in P. aeruginosa load. 
That is to say, changes in the microbiota induced by acute changes in antibiotic 
administration during the 28-day treatment periods may have masked the effect 
induced by ivacaftor.
In longer-term observational studies, a number of changes have been observed. 
Bernarde et al. [71] noted no significant changes in bacteria load and also no 
significant changes in overall community composition at 1 year following ivacaftor 
initiation. However, individual taxa were observed to change in that the rela-
tive abundance of Streptococcus mitis group was significantly diminished and a 
Porphyromonas OTU was significantly increased. Elsewhere, in perhaps the most 
comprehensive study of microbiological outcomes following ivacaftor initiation, 
Hisert et al. [72] found marked reductions in P. aeruginosa sputum densities using 
conventional culture and also reduced sputum inflammatory markers in regular 
follow-up throughout the first 2 years of ivacaftor use. These findings were mir-
rored in the 16S rRNA-based analysis, where decreases in mean P. aeruginosa 
relative abundance and subsequent increases in diversity measures were observed. 
However, no patient eradicated P. aeruginosa, and after 12 months of treatment, 
relative abundance, sputum counts and inflammatory markers began to increase 
again. The authors interpreted these findings to suggest that P. aeruginosa may adapt 
to a CFTR-restored environment and this clearly has implications for the need for 
ongoing anti-infective chemotherapy in CF.
11
The Pulmonary Microbiome in Cystic Fibrosis
DOI: http://dx.doi.org/10.5772/intechopen.91765
9. Nontuberculous mycobacteria
Nontuberculous mycobacteria (NTM) are identified in approximately 10% of CF 
patients, but only a small proportion will go on to develop NTM pulmonary disease 
(NTM-PD) warranting treatment. First and foremost, the management of CF pulmo-
nary disease should be optimised, including antibiotic therapy targeted to the indi-
vidual’s usual airway bacteria, prior to considering treatment for NTM-PD. Those who 
fulfil criteria for NTM lung disease may not necessarily require treatment and could be 
monitored expectantly if symptoms and radiographic findings are minimal or stable 
over a period of surveillance. However, the presence of Mycobacterium abscessus com-
plex (MABSC), deteriorating lung function, worsening radiology and/or anticipated 
lung transplant should prompt NTM therapy initiation (Table 2). For CF patients 
with Mycobacterium avium complex (MAC), recommended treatment includes 
triple antibiotic therapy with a macrolide, rifampin and ethambutol. Azithromycin 
is generally the preferred macrolide of choice in CF as it is better tolerated and has 
fewer drug–drug interactions. An initial course of injectable amikacin or streptomycin 
should be considered in the presence of (i) acid-fast bacillus smear-positive respira-
tory tract samples, (ii) radiological evidence of lung cavitation or severe infection and 
(iii) systemic signs of illness. MABSC treatment is more complicated and requires an 
induction phase (oral macrolide and two IV agents including amikacin with one or 
more additional intravenous antibiotics including tigecycline, imipenem, cefoxitin) 
for 3 to 12 weeks as well as a maintenance phase (nebulised amikacin and a macrolide 
with two to three oral antibiotics including minocycline, clofazimine, moxifloxacin, 
linezolid). Baseline and interval testing for drug toxicity is essential. The treatment 
duration for both MAC and MABSC is extended 1-year post-culture conversion. 
However, in patients who do not achieve culture negative status but tolerate therapy, 
ongoing treatment for mycobacterial suppression and prevention of disease progres-
sion can be considered. There are no randomised controlled trials of MABSC therapy 
in the general population or in CF; however, there is MABSC treatment outcome data 
in non-CF populations from several clinical studies [74]. In a study of 57 non-CF 
Clinical (both required)
1. Pulmonary symptoms with nodular or cavitary opacities on chest radiograph or a high-resolution CT 
scan that shows multifocal bronchiectasis with multiple small nodules
2. Appropriate exclusion of other diagnoses.
Microbiologic (one of the following required)
• Positive culture results from at least two expectorated sputum samples. If the results from samples are 
non-diagnostic, consider repeat sputum acid-fast bacillus (AFB) smears and cultures.
• Positive culture results from at least one bronchial wash or lavage.
• Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous 
inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologi-
cal features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that 
are culture positive for NTM.
• Expert consultation should be obtained when either infrequently encountered NTM or those usually 
representing environmental contamination are recovered.
• Patients who are suspected of having NTM-PD but who do not meet the diagnostic criteria should be 
followed up until the diagnosis is firmly established or excluded.
• Making the diagnosis of NTM-PD does not, per se, necessitate the institution of therapy, which is a 
decision based on potential risks and benefits of therapy for individual patients.
Table 2. 
ATS/IDSA clinical and microbiologic criteria for diagnosing nontuberculous mycobacterial pulmonary disease 
(NTM-PD) [73].
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subjects that compared M. abscessus ssp. massiliense and ssp. abscessus infections and 
treatment outcomes, all individuals were treated with clarithromycin-containing 
regimen in combination with an initial 4-week course of cefoxitin and amikacin, was 
given to 57 patients (24 with M. abscessus and 33 with M. massiliense) for more than 
12 months. The proportion of patients with sputum conversion and maintenance of 
negative sputum cultures was higher in patients with M. massiliense infection (88%) 
than in those with M. abscessus infection (25%; p < 0.001). Inducible resistance to 
clarithromycin (minimal inhibitory concentrations ≥ 32 μg/ml) was found in all tested 
M. abscessus isolates (n = 19), but in none of the M. massiliense isolates (n = 28) [75].
Inhaled liposomal amikacin for maintenance treatment has also drawn inter-
est. In a randomised placebo-controlled trial, CF subjects with NTM lung disease 
refractory to standard therapy were assigned to 590 mg OD inhaled liposomal 
amikacin or placebo, in addition to their standard CF treatments and ongoing 
NTM therapy [76]. The group of 90 patients was stratified based on MAC (64%) 
and MABSC (36%) [77]. At the end of the 6-month treatment period, there was a 
statistically significant increase in culture negativity overall and for the MAC group.
Reported NTM prevalence in CF ranges from 3 [78] to 23% [79]. The major-
ity (95%) of NTM isolated from CF patients are Mycobacterium avium complex 
(MAC) (M. avium-intracellulare and four M. avium subspecies) and M. abscessus 
complex (MABSC) (subspecies abscessus, massiliense, and bolletii) [80, 81]. Bryant 
et al. [82] reported the largest outbreak occurred in Cambridge, England, where 11 
of 31 patients with MABSC had a shared strain of M. abscessus subsp. massiliense with 
similar antibiotic resistance patterns by whole genome sequencing despite a lack of 
exposure to the same antibiotics, raising the possibility of cross infection amongst 
the CF cohort albeit conventional cross infection measures (Figure 2).
MABSC has been demonstrated to accelerate lung function decline in CF 
patients compared to uninfected CF controls [83, 84]. In CF, a common measure 
Figure 2. 
Typical treatment schedules for individuals with CF with Mycobacterium abscessus or MAC pulmonary 
disease [74].
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of lung disease severity is percent-predicted forced expiratory volume in 1 second 
(FEV1), with lower values indicating more severe lung disease. Qvist et al. showed 
that MABSC had a greater rate of FEV1% predicted decline than other organisms, 
including Pseudomonas aeruginosa and Burkholderia cepacia [84]. However, no lung 
function decline was noted in patients growing MAC [83]. Likewise, a large study 
found no significant effect of NTM infection on lung function decline, although 
analyses were not based on different NTM subtypes [80]. A diagnosis of NTM 
pulmonary disease must meet both clinical and microbiologic criteria as outlined by 
ATS guidelines, with exclusion of other aetiologies [73].
Individuals who are NTM culture positive but who do not meet ATS criteria 
for disease should be monitored closely [74]. Patients with CF meeting criteria for 
NTM-PD should be considered for therapy; however, treatment decisions should be 
individualised [74, 85]. It may be reasonable to monitor individuals with mild CF 
lung disease, MAC lung disease with mild symptoms and radiographic changes or a 
high possibility of drug intolerance or drug interactions [85]. However, CF patients 
with MABSC and/or severe CF lung disease should generally be treated in the 
absence of contraindications [85].
10. Fungal lung disease in CF
Clinical manifestations of respiratory fungal diseases in adult CF patients are 
very heterogeneous, ranging from asymptomatic colonisation to chronic infections, 
allergic disorders or invasive diseases in immunosuppressed CF patients following 
lung transplantation.
Aspergillus spp. are amongst the most widespread filamentous fungi in the 
environment, especially in areas with high humidity [86]. In CF patients, the 
most frequently isolated species is Aspergillus fumigatus, accounting for 67–73% 
of Aspergillus-positive sputum cultures [87]. Isolation of other species such as 
A. flavus, A. niger and A. terreus is less frequent but not rare (4, 4 and 2% of 
Aspergillus-positive sputum cultures, respectively) [87]. Notably, the prevalence of 
isolation of Aspergillus spp. from sputum cultures in CF patients increases with age, 
possibly reaching 46–78% in adult CF patients, although with important inter-
region and inter-centre variability [88–90]. However, knowledge of the prevalence 
of Aspergillus spp. isolation from sputum does not automatically allow to infer the 
prevalence of the various Aspergillus-related manifestations in CF patients, which 
range from asymptomatic colonisation to invasive diseases, especially in patients 
post-lung transplantation.
Allergic bronchopulmonary aspergillosis (ABPA) refers to a complex hypersen-
sitivity reaction which often occurs in patients affected by CF or asthma. ABPA is 
beyond the scope of discussion in this chapter.
In CF patients, the disease-related progressive damage of the lungs may favour 
the development of chronic Aspergillus infection, commonly defined as ‘Aspergillus 
bronchitis’, although aspergilloma(s) might also develop in some cases, especially 
in pre-existing cavities or bronchiectasis [91–93]. Aspergillus bronchitis has an 
estimated prevalence of ~2–8% in CF patients and may be suspected in the case of 
pulmonary exacerbation unresponsive to antibacterial treatment [94, 95]. As per 
Baxter et al.’s [96] classification, diagnosis of Aspergillus bronchitis can be made in 
the presence of a positive sputum galactomannan, high levels of Aspergillus-specific 
IgG and negative total and Aspergillus-specific IgE. Since Aspergillus bronchitis does 
reflect infection and not an immune-mediated response as in ABPA, corticosteroids 
are not the cornerstone of treatment. Treatment with azole derivatives is the cur-
rent standard of care, although the overall duration of treatment is still not clearly 
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defined [97]. Invasive aspergillosis is described as the infection progresses across 
tissues and invades the vessels, with subsequent necrosis [96]. Usually, invasive 
aspergillosis is observed in severely immunocompromised non-CF populations, 
such as haematology patients with prolonged neutropenia and patients receiv-
ing high dosages of corticosteroids or other immunosuppressive agents. Clinical 
symptoms usually include fever, chest pain, shortness of breath and/or cough [96]. 
Haemoptysis and pneumothorax might also develop in some cases [98, 99]. Invasive 
aspergillosis is rarely seen in patients affected by CF. However, it could develop 
in end-stage CF patient and in immunosuppressed CF patients following lung 
transplantation, frequently in the form of Aspergillus tracheobronchitis, occur-
ring mainly in the first 3 months after transplants and associated with increased 
mortality (39%) [100, 101]. Frequent symptoms of Aspergillus tracheobronchitis 
are severe dyspnoea, cough and wheezing [97]. The histopathological examination 
may show different features: (1) obstructive bronchial aspergillosis; (2) ulcerative 
tracheobronchitis (characterised by the invasion of the tracheobronchial mucosa 
and cartilage); and (3) pseudomembranous tracheobronchitis (characterised by 
inflammation and invasion of the tracheobronchial tree). Invasive aspergillosis is 
usually treated with systemic azole therapy (possibly associated with nebulised 
amphotericin B in some cases of tracheobronchitis) [97]. The US guidelines recom-
mend a minimum of 6 to 12 weeks of therapy for patients with invasive pulmonary 
aspergillosis and at least 3 months in the case of Aspergillus tracheobronchitis [97].
11. Conclusion
The pulmonary microbiome of people with CF diverging significantly from that 
of the healthy individuals has been the focus of much research in the last 5 years 
often producing more questions than answers. As the disease progresses, com-
munity structure becomes progressively less diverse, most likely as a consequence 
of long-term aggressive antibiotic therapy. The impact of acute antibiotic therapy, 
antifungal treatments and CFTR modulators are less well defined, and prospective 
clinical trials with sputum biobanking are needed to answer these questions.
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